Reynders McVeigh Capital Management LLC Sells 35,409 Shares of Becton, Dickinson and Company $BDX

Key Points

• Reynders McVeigh Capital Management cut its stake in Becton, Dickinson by 48.9%, selling 35,409 shares and retaining 37,071 shares valued at about $7.19 million.
• Several large institutions increased holdings—Wellington Management added roughly 5.17 million shares and Vanguard about 4.22 million—leaving institutional ownership at 86.97%.
• BDX beat quarterly EPS ($2.91 vs. $2.81) but missed revenue, issued FY2026 guidance of 12.35–12.65 EPS, declared a $1.05 quarterly dividend (2.8% yield) and authorized a $10 million buyback program.

Reynders McVeigh Capital Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 48.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,071 shares of the medical instruments supplier's stock after selling 35,409 shares during the quarter. Reynders McVeigh Capital Management LLC's holdings in Becton, Dickinson and Company were worth $7,194,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. First Eagle Investment Management LLC boosted its position in Becton, Dickinson and Company by 13.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier's stock valued at $1,870,653,000 after acquiring an additional 1,208,218 shares in the last quarter. Veritas Asset Management LLP boosted its position in Becton, Dickinson and Company by 40.6% during the 3rd quarter. Veritas Asset Management LLP now owns 2,954,898 shares of the medical instruments supplier's stock valued at $553,068,000 after acquiring an additional 852,854 shares in the last quarter. Finally, Rakuten Investment Management Inc. bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $152,931,000. Institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. TD Cowen increased their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a "hold" rating in a research report on Wednesday, February 11th. Citigroup dropped their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating on the stock in a research report on Tuesday, February 10th. Zacks Research raised Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research report on Friday, April 10th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Finally, Bank of America increased their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a "neutral" rating in a research report on Monday, January 5th. Six investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $189.08.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $149.41 on Monday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a fifty day moving average price of $160.69 and a 200-day moving average price of $181.92. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The firm has a market cap of $42.54 billion, a PE ratio of 24.37, a P/E/G ratio of 10.65 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $4.49 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the business posted $3.43 EPS. The business's revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 12.52 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 1,102 shares of company stock worth $198,909. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.